WALTHAM, Mass. and SAN DIEGO--(BUSINESS WIRE)--Inverness Medical Innovations, Inc. (Amex: IMA) and Biosite Incorporated (Nasdaq: BSTE) today announced that the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Inverness’ proposed acquisition of Biosite pursuant to a cash tender offer of $92.50 per share has expired without a request for additional information.
